Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research[1][2].
Molecular Weight:
(144.38 kDa)
Purity:
99
CAS Number:
[2245966-28-1]
Target:
Human leukocyte immunoglobulin (Ig)-like receptors (LILR),SARS-CoV
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted